Tourmaline Bio

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Tourmaline Bio and buy or sell other stocks, ETFs, and their options commission-free!

About TRML

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. 

CEO
Sandeep C. Kulkarni, MD
CEOSandeep C. Kulkarni, MD
Employees
Employees
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2021
Founded2021
Employees
Employees

TRML Key Statistics

Market cap
1.23B
Market cap1.23B
Price-Earnings ratio
-13.97
Price-Earnings ratio-13.97
Dividend yield
Dividend yield
Average volume
Average volume
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$48.27
52 Week high$48.27
52 Week low
$11.56
52 Week low$11.56

Stock Snapshot

As of today, Tourmaline Bio(TRML) shares are valued at $47.98. The company's market cap stands at 1.23B, with a P/E ratio of -13.97.

On 2026-07-25, Tourmaline Bio(TRML) shares started trading at —, with intraday highs of — and lows of —.

Trading activity shows a volume of 0.

Over the past 52 weeks, Tourmaline Bio(TRML) stock has traded between a high of $48.27 and a low of $11.56.

Over the past 52 weeks, Tourmaline Bio(TRML) stock has traded between a high of $48.27 and a low of $11.56.

People also own

Based on the portfolios of people who own TRML. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.